Clinical Trial

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Study acronym: TebeMRD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma. This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-03-29; most recent amendment 2025-07-14.
Status change: Recruiting → Active, Not Recruiting 2025-07-14
Status change: Not Yet Recruiting → Recruiting 2022-07-28
Trial Details
NCT Number NCT05315258
Lead Sponsor University of Oxford
Collaborators: Immunocore Ltd
Conditions Melanoma (Skin), Melanoma, Uveal
Enrollment 850 participants
Start Date 2022-07-25
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-17